Medical News

RSS

Isis Pharmaceuticals licenses second anti-cancer drug candidate to Lilly

Isis Pharmaceuticals announced today that Eli Lilly and Company licensed LY2275796, a second-generation antisense anti-cancer drug candidate for clinical development.

20 Sep 2004

Bonviva, to treat osteoporosis, submitted for marketing authorisation in Europe

Roche and GlaxoSmithKline announced today the submission of a Marketing Authorisation Application to the European authorities for a novel, once-monthly oral formulation of their new bisphosphonate, Bonviva (ibandronate), for the treatment of postmenopausal osteoporosis.

20 Sep 2004

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche announced today that results from a randomized Phase III clinical study of the investigational drug Tarceva (erlotinib HCl), in combination with gemcitabine chemotherapy met its primary endpoint of improving survival.

20 Sep 2004

Dementia is set to become one of the greatest health challenges for the Australian community

Australian Medical Association Vice-President, Dr Mukesh Haikerwal, said today that dementia is set to become one of the greatest health challenges for the Australian community over the next decade.

20 Sep 2004

New Australian biotech speeds up healing for burns and wounds

A Queensland PhD student’s discovery speeds up tissue growth and repair and sparks off a new listed biotech company.

20 Sep 2004

Breakthrough in spinal regeneration research

University of Queensland researchers are claiming a breakthrough in spinal regeneration research with the discovery of a molecule that blocks regrowth of damaged nerve processes.

20 Sep 2004

Laws against driving while using cell phones would have little effect on the number of accidents

In a new study issued by the American Enterprise Institute-Brookings Joint Center for Regulatory Studies, Prieger found that, while still at increased risk, drivers who use cell phones are less likely to have accidents by as much as 36 percent than previous studies predicted.

20 Sep 2004

Today’s scientists have the skills and experience to transplant a human face

A University of Louisville-led research team studying the face transplant has developed guidelines it says are critical to the success of the still-untried procedure.

20 Sep 2004

Less radiation in a more tailored manner best for uterine cancer

Less radiation, delivered in a more tailored manner, is very effective and should be preferred over longer-term conventional radiation therapy in treating one of the most virulent forms of uterine cancer

20 Sep 2004

Liver cancer, cirrhosis of the liver and other diseases related to hepatitis B infection will continue to increase

Liver cancer, cirrhosis of the liver and other diseases related to hepatitis B infection will continue to kill people in the prime of life and burden health systems with chronically sick people unless childhood immunization against hepatitis B is stepped up

20 Sep 2004

Resveratrol in red wine, is thought to contribute to improved cardiovascular effects associated with moderate consumption of red wine

Researchers funded by the National Science Foundation (NSF) and affiliated with the Salk Institute in San Diego, Calif., have succeeded in converting chalcone synthase, a biosynthetic protein enzyme found in all higher plants, into an efficient resveratrol synthase.

20 Sep 2004

Genome researchers to look at 1918 Spanish flu

University of Washington researchers will be taking part in a multi-site project examining a portion of the genome of the strain of influenza responsible for the "Spanish Flu" outbreak in 1918.

20 Sep 2004

FDA approval for small vessel cobalt chromium coronary stent

Guidant Corporation has announced U.S. Food and Drug Administration (FDA) approval of the company’s newest stent system designed to treat coronary artery disease in small vessels in patients with abrupt or threatened abrupt closure.

20 Sep 2004

Lack of recognition an influential factor for some women who decide not to have children

In an atmosphere of increasing public concern over Australia's falling national birthrate, a Monash University study has found lack of recognition of the contribution mothers make to society is an influential factor for some women who decide not to have children.

20 Sep 2004

Protein points to anticancer drug targets

A unique tail at one end of a protein called Ubc12 stabilizes a molecular workshop that assembles the “on-switch cells” used to accelerate cell replication.

20 Sep 2004

BBC focuses on the rise of complementary or alternative medicines

Broadcaster Anna Ford investigates why people are turning to CAM in a new six part BBC Radio Four series, The Other Medicine. Is there any evidence that CAM works, is it harmful and should the CAM industry, worth £1.6 billion a year, be made more available on the NHS?

20 Sep 2004

Increase in cases of pertussis (whooping cough) in Indiana

Pertussis is a contagious illness caused by bacteria. It occurs in infants and young children more often than older children and adults. Adults with milder, undiagnosed symptoms can transmit the disease to infants and children.

20 Sep 2004

29 percent of California women mistakenly believe a cold or flu should be treated with an antibiotic

Illustrating the extent of Americans’ lack of knowledge about antibiotics, 29 percent of California women queried mistakenly believe a cold or flu should be treated with an antibiotic, according to results of a survey being presented at the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA).

20 Sep 2004

European positive for Cymbalta and Xeristar

Eli Lilly and Company and Boehringer Ingelheim have announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes.

20 Sep 2004

Crucell and AIDS Vaccine Initiative have signed an exclusive license agreement to develop an AIDS vaccine

Dutch biotechnology company Crucell and the International AIDS Vaccine Initiative (IAVI) have signed an exclusive license agreement to develop an AIDS vaccine based on Crucell’s AdVac® technology.

20 Sep 2004